Partnership combines Chenomx NMR suite with GeneGo's MetaCore and MetaDrug Discovery platform, providing researchers with the ability to perform sophisticated pathway analysis and visualisation
Chenomx, a provider of software and compound libraries for NMR-based metabolomics, and GeneGo, maker of data analysis systems for biology and pathway analysis, announce a partnership to provide metabolomics data integration between their software products.
"Chenomx's partnership with GeneGo offers several significant advantages to our shared customers," explains Jack Newton, director of product development for Chenomx.
"First, our customers will now be able to combine Chenomx NMR Suite's powerful metabolite identification and quantification capabilities with GeneGo's pathway analysis tools, thereby improving their interpretation and understanding of the underlying biology.
"This integration also allows our customers to integrate genomic and proteomic data sources with their Chenomx metabolomics data".
"We initiated this partnership based on customer requests for seamless functional analysis of their NMR and mass spec metabolomics data," said Julie Bryant, VP of business development.
"Metabolic data is hugely important in diagnostics and drug discovery, as any major disease fundamentally affects core biochemical pathways.
"Yet, MetaCore/MetaDrug is the only product in the field which enables direct parsing, pathway and network analysis of human metabolic data and its integration with genomics, proteomics and genetic data.
"Now, our customers will have this functionality accessed directly from Chenomx software".
